Compare · ARGX vs ARTV
ARGX vs ARTV
Side-by-side comparison of argenx SE (ARGX) and Artiva Biotherapeutics Inc. (ARTV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and ARTV operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $52.96B, about 218.7x ARTV ($242.2M).
- Over the past year, ARGX is up 50.5% and ARTV is up 502.5% - ARTV leads by 452.0 points.
- ARTV has been more active in the news (5 items in the past 4 weeks vs 4 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 7 for ARTV).
- Company
- argenx SE
- Artiva Biotherapeutics Inc.
- Price
- $853.73-5.62%
- $9.79+4.59%
- Market cap
- $52.96B
- $242.2M
- 1M return
- +4.55%
- +22.84%
- 1Y return
- +50.48%
- +502.46%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2024
- News (4w)
- 4
- 5
- Recent ratings
- 25
- 7
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx to Host Autoimmune Myositis R&D Webinar
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
- SEC Form 6-K filed by argenx SE
Latest ARTV
- Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
- Director Ra Capital Management, L.P. bought $4,599,903 worth of shares (531,326 units at $8.66) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by Artiva Biotherapeutics Inc.
- Director Ra Capital Management, L.P. bought $7,650,148 worth of shares (1,027,722 units at $7.44) (SEC Form 4)
- Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today
- The $13 Million Company Teaching the Immune System to Hunt Cancer
- Large owner Gc Corp. bought $16,499,992 worth of shares (1,432,291 units at $11.52) (SEC Form 4)
- Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
- SVP, Research and Development Raymon Heather sold $27,879 worth of shares (3,095 units at $9.01), decreasing direct ownership by 2% to 148,228 units (SEC Form 4) to satisfy withholding tax
- Chief Tech Operations Officer Horan Christopher sold $63,073 worth of shares (7,002 units at $9.01), decreasing direct ownership by 2% to 293,450 units (SEC Form 4) (for withholding tax)